Comparative safety of antipsychotics: Another look at the risk of diabetes

Canadian Journal of Psychiatry

Volumn 58, Issue 4, 2013, Pages 218-224

  Moisan, Jocelyne ^a,b   Turgeon, Mélanie ^c   Desjardins, Olivier ^d   Grégoire, Jean Pierre ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Institut National D'Excellence en Santé et en Services Sociaux   (Canada)

^d Abbott Canada   (Canada)

Author keywords

Antipsychotics; Case control study; Diabetes mellitus; Populationbased

Indexed keywords

CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CANADA; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY;

EID: 84878281086     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371305800407     Document Type: Article

References (33)

1. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2): 596-601.
2. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2): 290-296.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12): 1209-1223.
4. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5): 425-433.
5. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry. 2002;63(9): 758-762.
6. Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4): 266-271.
7. Yood MU, DeLorenze G, Quesenberry CP, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent - results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf. 2009;18: 791-799.
8. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63(10): 920-930.
9. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325(7358): 243-247.
10. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159(4): 561-566.
11. Moisan J, Grégoire J-P, Gaudet M, et al. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. Pharmacoepidemiol Drug Saf. 2005;14(6): 427-436.
12. Dunlop BW, Sternberg M, Phillips LS, et al. Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull. 2003;37(3): 99-117.
13. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol. 2006;164(7): 672-681.
14. Farwell WR, Stump TE, Wang J, et al. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med. 2004;19(12): 1200-1205.
15. Lambert BL, Chou CH, Chang KY, et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf. 2005;14(6): 417-425.
16. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12- week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007;68(11): 1733-1740.
17. Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;56(2): 164-170.
18. Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis. 2005;193(6): 387-395.
19. Barnett M, Argo T, Alexander B, et al. A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors. Ann Clin Psychiatry. 2006;18(1): 1-7.
20. Moisan J, Grégoire J-P. Patterns of discontinuation of atypical antipsychotics in the province of Québec: a retrospective prescription claims database analysis. Clin Ther. 2010;32(Suppl A):S21-S31.
21. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006;186(4): 572-578.
22. Cohen D, Dekker JJ, Peen J, et al. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to longterm antipsychotic treatment. Eur Neuropsychopharmacol. 2006;16(3): 187-194.
23. Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol. 2005;20(2): 105-112.
24. Blonde L, Kan HJ, Gutterman EM, et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry. 2008;69(5): 741-748.
25. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48(8): 999-1009.
26. World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical (ATC) classification index. Oslo (NO): WHO 2007.
27. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.
28. Belsley D, Kuh E, Welsch R. Regression diagnostics: identifying influential data and sources of collinearity. New York (NY): Wiley; 1980.
29. SAS Institute Inc. SAS OnlineDoc 9.1 [Internet]. Cary (NC): SAS Institute Inc; 2004 [cited 2006]. Available from: http://support.sas.com/91doc/ docMainpage.jsp.
30. Lipscombe LL, Levesque LE, Gruneir A, et al. Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. Am J Geriatr Psychiatry. 2011;19(12): 1026-1033.
31. Cooper D, Moisan J, Gaudet M, et al. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Can J Psychiatry. 2005;50(14): 901-908.
32. Spoelstra JA, Stolk RP, Cohen D, et al. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry. 2004;65(5): 674-678.
33. Gianfrancesco F, White R, Wang RH, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003;23(4): 328-335.